---
title: Magnetic pulses reduce movement stiffness
nct_id: NCT07306104
phase: NA
status: RECRUITING
sponsor: University of Southern Denmark
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07306104"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07306104"
last_fetched: "2026-05-10T14:03:31.245Z"
source: "Parkinson's Pathways (curated)"
---
# Magnetic pulses reduce movement stiffness

**Goal (in five words):** Magnetic pulses reduce movement stiffness

**Official Title:** The Effect of Long-term Treatment of Parkinson's Disease With T-PEMF

**Trial ID:** [NCT07306104](https://clinicaltrials.gov/study/NCT07306104)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University of Southern Denmark
- **Target Enrollment:** 90 participants
- **Start Date:** 2026-02-16
- **Completion Date:** 2028-01
- **Conditions:** PARKINSON DISEASE (Disorder)
- **Interventions:** Transcranial pulsed electromagnetic fields (T-PEMF), Sham (No Treatment)
- **Intervention Types:** DEVICE

## Summary For Families

Testing whether long-term sessions of transcranial pulsed electromagnetic fields can ease motor symptoms and support brain function in people with mild Parkinson's. The treatment uses noninvasive electromagnetic pulses over the scalp to gently modulate brain activity and promote neuroplasticity, and it is compared with a sham procedure while participants stay on their usual, stable Parkinson medications rather than replacing levodopa. Adults 18 and up with idiopathic Parkinson's at Hoehn and Yahr stage 1 or 2 who can follow procedures and have an MMSE score over 22 may qualify; people with brain implants, epilepsy, recent medication changes, certain anticoagulant use, prior stroke, pregnancy, or other neurological disorders are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Intervention Groups

Inclusion Criteria:

* Diagnosed with idiopathic Parkinson's disease
* The participant must be able to understand, accept, and complete the planned procedures
* Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2
* Mini Mental-State Examination score \> 22

Exclusion Criteria:

* Cancer in the brain, neck, or head area
* Presence of active medical implants
* Epilepsy
* Alcoholism
* Substance abuse
* Open wound on the scalp
* Severe psychopathological disorders
* Pregnancy
* Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment
* Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep
* Neurological disease other than Parkinson's disease
* Previous stroke
* Reduced motor function caused by conditions other than Parkinson's disease

Control Group with Parkinson's Disease

Inclusion Criteria:

* Diagnosed with idiopathic Parkinson's disease
* The patient must be able to understand, accept, and complete the planned procedures
* Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2
* Mini Mental-State Examination score \> 22

Exclusion Criteria:

* Neurological disease other than Parkinson's disease
* Reduced motor function caused by conditions other than Parkinson's disease

Healthy Reference Group:

Inclusion Criteria:

-The patient must be able to understand, accept, and complete the planned procedures

Exclusion Criteria:

* Neurological disease
* Reduced motor function caused by condition
```

## Locations (2)

- Odense University Hospital, Odense, Denmark _(55.3959, 10.3883)_
  - Christian Winterberg, MD — (CONTACT) — +45 65411833 — christian.winterberg@rsyd.dk
  - Christian Winterberg, MD — (PRINCIPAL_INVESTIGATOR)
- University of Southern Denmark, Odense, Denmark _(55.3959, 10.3883)_
  - Anne Sofie Bøgh Malling, Ph.d. — (CONTACT) — +45 28903733 — amalling@health.sdu.dk
  - Jens Bojsen-Møller, Ass. proffessor — (CONTACT) — jbojsen@health.sdu.dk
  - Anne Sofie B Malling, Ph.d. — (PRINCIPAL_INVESTIGATOR)
  - Mikkel C Juhl, MSc — (SUB_INVESTIGATOR)
  - Morten Meyer, Professor — (SUB_INVESTIGATOR)
  - Bente R Jensen, Professor — (SUB_INVESTIGATOR)
  - Jens Bojsen-Møller, Ass. Professor — (SUB_INVESTIGATOR)

## Central Contacts

- Anne Sofie Bøgh Malling, Ph.d. — (CONTACT) — +45 28903733 — amalling@health.sdu.dk
- Bente Rona Jensen, Professor — (CONTACT) — brjensen@health.sdu.dk

---

*Canonical: https://parkinsonspathways.com/trial/NCT07306104*  
*HTML version: https://parkinsonspathways.com/trial/NCT07306104*  
*Source data: https://clinicaltrials.gov/study/NCT07306104*